Cytek Biosciences, Inc. (NasdaqGS:CTKB) will look for M&A. William McCombe Chief Financial Officer said during the Goldman Sachs 45th Annual Global Healthcare Conference, "M&A opportunities are episodic. You were not going to stretch to do a deal just because we have the cash available. We're only going to do deals if we think that they're synergistic and that they're well priced and that we can integrate them well.

So given that we're generating positive cash and that we think our stock is very attractively valued, the Board decided to reinitiate the program. And so we'll keep plenty of dry powder for M&A opportunities, but given that we're generating excess cash flow, we thought that our stock was compelling opportunity to put some of that to work. So we'll continue to do share repurchase as we see the opportunity to do that at good prices, we're fortunate that we have the opportunity to do both M&A and share repurchase from time to time.

So we'll manage it on a case-by-case basis as we see opportunities. And as we look at where our stock is trading, there's no sort of mechanical formula beyond that. We'll just be opportunistic".